Studies related to Pain and Creatine

An Open-label Study Adding Creatine Monohydrate To Ongoing Medical Regimens In Patients With The Fibromyalgia Syndrome

Effect Increase
Values Although there was a statistically signifiacnt improvement in brief pain inventory scores, the lack of a placebo group and small sample size makes it difficult to ascertain the clinical significance of these changes. Mean and SD. Brief pain inventory average worst pain, range 0-10. Baseline: 6.92 ± 2.61. Maximum improvement during treatment: 5.17 ± 1.80. End of follow up: 7.00 ± 1.95. Significance during 12 week study: p = 0.09. Baseline vs. maximum improvement: p = 0.03. Maximum improvement vs end of follow up: p = 0.02. Brief pain inventory average pain severity, range 0-10. Baseline: 4.75 ± 1.50. Maximum improvement during treatment: 3.48 ± 1.71. End of follow up: 5.65 ± 2.25. Significance of trend during 12 week study: p = 0.09. Baseline vs. maximum improvement: p = 0.03. Maximum improvement vs. end of follow up: 0.02. Brief pain inventory interference from pain, range 0-10. Baseline: 5.00 ± 2.08. Maximum improvement during treatment: 3.48 ± 1.71. End of follow up: 5.39 ± 2.51. Significance of trend during 12 week study: 0.10. Baseline vs maximum improvement: p = 0.01. Maximum improvement vs. end of follow up: p = 0.04
Trial Design Non-controlled trial
Trial Length 1-6 months
Number of Subjects 30
Sex Both Genders
Notes for this study:
In this 8-week non-controlled trial, 30 people with fibromyalgia were given 3 g of creatine (in 1000 mg tablets) for 3 weeks, which was then increased to 5 g daily for the remaining 5 weeks. Measurements of symptoms of fibromyalgia, quality of life, sleep, disability, and pain were done at baseline, at 4 weeks, after the 8 week intervention, and 4 weeks after the intervention.

Although there were improvements in all of the primary measures, these improvements were not found at the 4 week follow up assessments.

It is important to note that only 12 of the 30 participants were assessed for the final analysis, as the rest of the participants either withdrew, not able to comply with the intervention or were lost to follow-up.